Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of Nigella sativa Linn
MetadataShow full item record
© 2017. Thymoquinone (TQ), isolated almost fifty years ago, is the main bioactive constituent of black seed essential oil extracted from the seed of Nigella sativa. TQ has been shown to have promising effects against a variety of inflammatory diseases and cancer. Cancer development is a multistep process where normal cells acquire qualities that enable the cells to proliferate continuously and migrate to distant sites in the human body. Drugs that interfere with this process are considered potential anti-cancer therapeutics, which may ultimately result in their clinical usage. TQ is once such compound which has been reported to modulate several major signaling pathways and key oncogenic molecules that play a prominent role in cancer initiation, progression, invasion, metastasis, and angiogenesis. Various studies have reported that TQ can enhance the anti-cancer potential when co-administered with several chemotherapeutic agents while reducing their toxic side effects. In addition, TQ has been shown to inhibit the growth of breast, prostate, pancreatic, colon, lung, and hematological malignancies in different mouse models of cancer. This review focuses on TQ's chemical and pharmacological properties, its diverse molecular targets and also provides clear evidence on its promising potential under preclinical and clinical settings.
Showing items related by title, author, creator and subject.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer CollaborationFitzmaurice, C.; Allen, C.; Barber, R.; Barregard, L.; Bhutta, Z.; Brenner, H.; Dicker, D.; Chimed-Orchir, O.; Dandona, R.; Dandona, L.; Fleming, T.; Forouzanfar, M.; Hancock, J.; Hay, R.; Hunter-Merrill, R.; Huynh, C.; Hosgood, H.; Johnson, C.; Jonas, J.; Khubchandani, J.; Kumar, G.; Kutz, M.; Lan, Q.; Larson, H.; Liang, X.; Lim, S.; Lopez, A.; MacIntyre, M.; Marczak, L.; Marquez, N.; Mokdad, A.; Pinho, C.; Pourmalek, F.; Salomon, J.; Sanabria, J.; Sandar, L.; Sartorius, B.; Schwartz, S.; Shackelford, K.; Shibuya, K.; Stanaway, J.; Steiner, C.; Sun, J.; Takahashi, K.; Vollset, S.; Vos, T.; Wagner, J.; Wang, H.; Westerman, R.; Zeeb, H.; Zoeckler, L.; Abd-Allah, F.; Ahmed, M.; Alabed, S.; Alam, N.; Aldhahri, S.; Alem, G.; Alemayohu, M.; Ali, R.; Al-Raddadi, R.; Amare, A.; Amoako, Y.; Artaman, A.; Asayesh, H.; Atnafu, N.; Awasthi, A.; Saleem, H.; Barac, A.; Bedi, N.; Bensenor, I.; Berhane, A.; Bernabé, E.; Betsu, B.; Binagwaho, A.; Boneya, D.; Campos-Nonato, I.; Castañeda-Orjuela, C.; Catalá-López, F.; Chiang, P.; Chibueze, C.; Chitheer, A.; Choi, J.; Cowie, B.; Damtew, S.; Das Neves, J.; Dey, S.; Dharmaratne, S.; Dhillon, P.; Ding, E.; Driscoll, T.; Ekwueme, D.; Endries, A.; Farvid, M.; Farzadfar, F.; Fernandes, J.; Miller, Ted (2017)Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability ...
Towards understanding disparities in cancer outcomes for Aboriginal Australians: exploring Aboriginal perceptions and experiences of cancer in Western AustraliaShahid, Shaouli (2010)Cancer has become one of the major chronic diseases among Aboriginal and Torres Strait Islander people of Australia, and was declared a health priority in the National Aboriginal and Torres Strait Islander Health Strategy ...
Rates of colonoscopy in the 3 years prior to a diagnosis of colorectal cancer in Western Australia: assessment of risk factors for missed and interval cancers. Preliminary results from a population-based studySalama, M.; Harma, C.; Fritschi, Lin; Heyworth, J.; Raftopoulos, S.; Ee, H. (2014)Introduction and Aims: Colonoscopy is the gold standard for diagnosing colorectal cancer (CRC) however there is a miss rate for cancers of up to 7.9%, with significant variability in this figure from different populations ...